While our review shows the use of BTK inhibitors in the management of autoimmune bullous diseases associated with advanced lymphoproliferative malignancies, such as CLL, this case demonstrates its efficacy in the management of early lymphoproliferation. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.